Numerate said this week that Merck will use its in silico drug design platform to generate small-molecule drug leads for an undisclosed cardiovascular disease target.
Financial details of the agreement were not disclosed.
Numerate's CEO Guido Lanza said in statement that the company was "pleased" to add Merck to its client list.
That list includes Boehringer Ingelheim, whose researchers are using the platform to generate drug leads for an unnamed infectious disease target (BI 12/09/11).